SOPHiA GENETICS president sells 2,800 shares for taxes

SOPHiA GENETICS SA President Ross Muken completed an open-market sale of 2,800 Ordinary Shares at a weighted average price of $4.9597 per share.

Rhea-AI Filing Summary

SOPHiA GENETICS SA President Ross Muken completed an open-market sale of 2,800 Ordinary Shares at a weighted average price of $4.9597 per share. After this transaction, he directly holds 682,432 shares. The sale was made to cover tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026 and was executed under a pre-established Rule 10b5-1(c) trading plan, meaning it did not represent a discretionary trade.

Insider Trade Summary 10b5-1

Net Seller: 2,800 shares

Net Sell 1 txn

Insider Muken Ross

Role President

Sold 2,800 shs ($14K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	2,800	$4.9597	$14K

Holdings After Transaction: Ordinary Shares — 682,432 shares (Direct)

Footnotes (2)

1. F1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.75 to $5.16, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 2,800 shares Weighted average sale price: $4.9597 per share Post-transaction holdings: 682,432 shares +2 more

5 metrics

Shares sold 2,800 shares Open-market sale on April 14, 2026

Weighted average sale price $4.9597 per share Ordinary Shares sold in multiple transactions

Post-transaction holdings 682,432 shares Directly owned by Ross Muken after sale

Price range of sales $4.75–$5.16 per share Range of individual trade prices for 2,800 shares

Net shares sold 2,800 shares Net-sell direction per transaction summary

Key Terms

Rule 10b5-1(c) trading plan, tax withholding obligations, restricted stock units, weighted average price, +1 more

5 terms

Rule 10b5-1(c) trading plan regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan"

A Rule 10b5-1(c) trading plan is a legally defined, pre-set schedule that lets company insiders automatically buy or sell stock at specified times or under set formulas when they are not in possession of undisclosed, sensitive information. Think of it like an automatic payment plan for trades: because the instructions are written in advance, trades under the plan help protect insiders from allegations of trading on secret information and give investors clearer expectations about when insiders will transact, which can affect liquidity and perceived transparency.

tax withholding obligations financial

"sold ... in the open market to satisfy tax withholding obligations arising in connection with the vesting"

restricted stock units financial

"tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"Represents shares sold by the Reporting Person in the open market"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SOPHiA GENETICS (SOPH) report for Ross Muken?

SOPHiA GENETICS reported that President Ross Muken sold 2,800 Ordinary Shares. The sale was an open-market transaction to cover tax withholding obligations tied to recently vested restricted stock units, and it was executed under a pre-established Rule 10b5-1(c) trading plan.

At what price did Ross Muken sell SOPHiA GENETICS (SOPH) shares?

The reported weighted average sale price was $4.9597 per share. Footnotes state the 2,800 shares were sold in multiple transactions at prices ranging from $4.75 to $5.16, and detailed breakdowns are available on request from the company or the SEC staff.

How many SOPHiA GENETICS (SOPH) shares does Ross Muken hold after this sale?

After the 2,800-share sale, Ross Muken directly holds 682,432 Ordinary Shares. This indicates the transaction was small relative to his overall position, and the filing characterizes it as a tax-related sale rather than a discretionary portfolio change.

Why did Ross Muken sell SOPHiA GENETICS (SOPH) shares according to the Form 4?

The filing explains the sale was made to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. It emphasizes these sales were executed under a pre-established Rule 10b5-1(c) trading plan and were not discretionary trades.

What does the Rule 10b5-1(c) trading plan note mean in the SOPHiA GENETICS (SOPH) Form 4?

The Form 4 states the sales were effected under a pre-established Rule 10b5-1(c) trading plan. Such plans allow insiders to schedule trades in advance, helping separate routine liquidity or tax-related transactions from discretionary decisions based on current market conditions.

How is the sale price range for SOPHiA GENETICS (SOPH) shares described in the filing?

The filing notes that the reported price is a weighted average and that shares were sold in multiple trades between $4.75 and $5.16. It also states the reporting person will provide full price-by-trade details to the issuer, shareholders, or SEC staff upon written request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Muken Ross

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/14/2026		S		2,800(1)	D	$4.9597(2)	682,432	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.75 to $5.16, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Ross Muken	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)